Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study.

BMC Pharmacol Toxicol · 2024 · PMC11027409 · PMID 38641625

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

During two week treatment, inflammatory indexes of Early Antibody Group and Control Group manifested decreasing trends while those of Late Antibody Group presented an increasing trend before decreasing.(Supplemental Table 2 ).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.